Focal and Segmental Glomerulosclerosis: Multiple Pathways Are Involved

Seminars in Nephrology

Volumn 31, Issue 4, 2011, Pages 326-332

  Meyrier, Alain ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Calcineurin inhibitors; Focal segmental glomerulosclerosis; Genetic FSGS; Glucocorticoids; Idiopathic nephrotic syndrome; Pathogenesis; Podocyte; Posttransplant recurrence; Slit diaphragm proteins

Indexed keywords

ACTIN; AGRIN; ALPHA ACTININ 4; ALPHA DYSTROGLYCAN; BEVACIZUMAB; CALCINEURIN INHIBITOR; CD2 ASSOCIATED PROTEIN; CYCLOSPORIN A; DEXAMETHASONE; ELONGATION FACTOR 1ALPHA; GLUCOCORTICOID; GLUCOSE; LAMININ; MYOSIN IIA; P CADHERIN; PHOSPHATIDYLINOSITOL 3 KINASE; PODOCALYXIN; PODOCIN; PODOPLANIN; PROTEIN ZO1; RITUXIMAB; SYNAPTOPODIN; TACROLIMUS; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; TUBULIN; VASCULOTROPIN; VASCULOTROPIN C; VERY LATE ACTIVATION ANTIGEN 3; WT1 PROTEIN;

ARTICLE; CELL STRUCTURE; CELL SURVIVAL; CYTOSKELETON; DIABETIC NEPHROPATHY; EPITHELIAL MESENCHYMAL TRANSITION; FOCAL GLOMERULOSCLEROSIS; GENETIC DISORDER; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; HIV ASSOCIATED NEPHROPATHY; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LAMELLIPODIUM; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; SHEAR STRESS; SIGNAL TRANSDUCTION; VIRUS INFECTION;

ANIMALS; EPITHELIAL-MESENCHYMAL TRANSITION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEMODYNAMICS; HUMANS; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; PERMEABILITY; PODOCYTES; PROTEINURIA; RECURRENCE; STRESS, MECHANICAL;

EID: 79961242353     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2011.06.003     Document Type: Article

References (57)

1. Meyrier A. Mechanisms of disease: focal segmental glomerulosclerosis. Nature Clin Pract Nephrol 2005, 1:44-54.
2. Thomas D.B., Franceschini N., Hogan S.L., Ten Holder S., Jennette C.E., Falk R.J., et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006, 69:920-926.
3. Barisoni L., Schnaper H.W., Kopp J.B. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2007, 2:529-542.
4. Wiggins R.C. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 2007, 71:1205-1214.
5. Reiser J., Gupta V., Kistler A.D. Toward the development of podocyte-specific drugs. Kidney Int 2010, 77:662-668.
6. Morton M.J., Hutchinson K., Mathieson P.W., Witherden I.R., Saleem M.A., Hunter M. Human podocytes possess a stretch-sensitive, Ca2+-activated K+ channel: potential implications for the control of glomerular filtration. J Am Soc Nephrol 2004, 5:2981-2987.
7. Haraldsson B., Nyström J., Deen W.M. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008, 88:451-487.
8. Matsusaka T., Xin J., Niwa S., Kobayashi K., Akatsuka A., Hashizume H., et al. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 2005, 16:1013-1023.
9. Wiggins J.E., Goyal M., Sanden S.K., Wharram B.L., Shedden K.A., Misek D.E., et al. Podocyte hypertrophy, "adaptation", and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol 2005, 16:2953-2966.
10. Kretzler M. Role of podocytes in focal sclerosis: defining the point of no return. J Am Soc Nephrol 2005, 16:2830-2832.
11. Stokes M.B., Valeri A.M., Markowitz G.S., D'Agati V.D. Cellular focal segmental glomerulosclerosis: clinical and pathologic features. Kidney Int 2006, 70:1783-1792.
12. Kambahm N., Markovitz G.S., Valeri A.M., D'Agati V.D. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001, 59:1498-1509.
13. Herlitz L.C., Markowitz G.S., Farris A.B., Schwimmer J.A., Stokes M.B., Kunis C. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol 2010, 21:163-172.
14. Chiang C.K., Inagi R. Glomerular diseases: genetic causes and future therapeutics. Nat Rev Nephrol 2010, 6:539-554.
15. Nabet B., Tsai A., Tobias J.W., Carstens R.P. Identification of a putative network of actin-associated cytoskeletal proteins in glomerular podocytes defined by co-purified mRNAs. PLoS One 2009, 4:e6491.
16. Kopp J.B. Dystroglycan in the molecular diagnosis of the podocytopathies. Clin J Am Soc Nephrol 2009, 4:1696-1698.
17. Krendel M., Kim S.V., Willinger T., Wang T., Kashgarian M., Flavell R., et al. Disruption of myosin 1e promotes podocyte injury. J Am Soc Nephrol 2009, 20:86-94.
18. Kopp J.B., Smith M.W., Nelson G.W., Johnson R.C., Freedman B.I., Bowden D.W., et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40:1175-1184.
19. Kopp J.B., Winkler C.A., Nelson G.W. MYH9 genetic variants associated with glomerular disease: what is the role for genetic testing?. Semin Nephrol 2010, 30:409-417.
20. Genovese G., Tonna S.J., Knob A.U., et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int 2010, 78:698-704.
21. Meyrier A. An update on the treatment options of focal segmental glomerulosclerosis. Expert Opin Pharmacother 2009, 10:315-328.
22. Brown E.J., Schlöndorff J.S., Becker D.J., et al. Mutations in the formin protein INF2 causes focal segmental glomerulosclerosis. Nat Genet 2010, 42:72-76.
23. Winn M.P. Young Investigator Award: TRP'ing into a new era for glomerular diseases. J Am Soc Nephrol 2008, 19:1071-1075.
24. Liu Y. New insights into epithelial-mesenchymal transition in kidney. J Am Soc Nephrol 2010, 21:2122.
25. Sam R., Wanna L., Gudehithlu K.P., Garber S.L., Dunea G., Arruda J.A. Glomerular epithelial cells transform to myofibroblasts: early but not late removal of TGF-beta1 reverses transformation. Transl Res 2006, 148:142-148.
26. Boor P., Ostendorf T., Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010, 6:643-656.
27. Friedrich C., Endlich N., Kriz W., Endlich K. Podocytes are sensitive to fluid shear stress in vitro. Am J Physiol Renal Physiol 2006, 291:F856-F865.
28. Foster R.R., Satchell S.C., Seckley J., Emmett M.S., Joory K., Xing C.Y., et al. VEGF-C promotes survival in podocytes. Am J Physiol Renal Physiol 2006, 291:F196-F207.
29. Parikh S.M., Pollack M.R. VEGF receptors and glomerular function. J Am Soc Nephrol 2010, 21:1599-1600.
30. Müller-Deile J., Worthmann K., Saleem M., Tossidou I., Haller H., Schiffer M. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol Renal Physiol 2009, 297:F1656-F1667.
31. Isermann B., Vinnikov I.A., Madhusudhan T., Hersog S., Kashif M., Blautzik J., et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007, 13:1349-1358.
32. dn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis. Am J Physiol Renal Physiol 2009, 296:F819-F829.
33. Drossopoulou G.I., Tsotakos N.E., Tsilibary E.C. Impaired transcription factor interplay in addition to advanced glycation end products suppress podocalyxin expression in high glucose-treated human podocytes. Am J Physiol Renal Physiol 2009, 297:F594-F603.
34. Shalhoub R.J. Pathogenesis of lipoid nephrosis: a disorder of T cell function. Lancet 1974, 2:556-559.
35. Meyrier A. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis?. Kidney Int 2009, 76:487-491.
36. Ponticelli C., Glassock R.J. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol 2010, 5:2363-2372.
37. Weber S., Gribouval O., Esquivel E.L., Morinière V., Tête M.J., Legendre C. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplantation recurrence. Kidney Int 2004, 66:571-579.
38. Waldman M., Marshall V., Whitby D., Kopp J.B. Viruses and kidney disease: beyond HIV. Semin Nephrol 2008, 26:595-607.
39. Li R.M., Branton M.H., Tanawattanacharoen S., Falk R.A., Jennette J.C., Kopp J.B. Molecular identification of SV40 infection in human subjects and possible association with kidney disease. J Am Soc Nephrol 2002, 13:2320-2330.
40. Waldman M., Kopp J.B. Parvovirus B19 and the kidney. Clin J Am Soc Nephrol 2007, 2:S47-S56.
41. Santin S., Garcia-Maset R., Ruiz P., Giménez I., Zamora I., Pena A. Nephrin mutations cause childhood-and adult-onset focal segmental glomerulosclerosis. Kidney Int 2009, 76:1268-1276.
42. Cattran D.C., Alexopoulos E., Heering P., Hoyer P.F., Johnston A., Meyrier A., et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int 2007, 72:1429-1447.
43. Westhoff T.H., Van der Giet M. Tacrolimus in the treatment of idiopathic nephrotic syndrome. Expert Opin Investig Drugs 2007, 16:1099-1110.
44. Nakayama M., Kamei K., Nozu K., Matsuoka K., Nakagawa A., Sako M., et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 2008, 23:481-485.
45. Kurosaki T. Paradox of B cell-targeted therapies. J Clin Invest 2008, 118:3260-3263.
46. Fujii Y., Khoshnoodi J., Takenaka H., Hosoyamada M., Nakajo A., Bessho F., et al. The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases. Kidney Int 2006, 69:1350-1359.
47. Xing C.Y., Saleem M.A., Coward R.J., Ni L., Witherden I.R., Mathieson P.W. Direct effect of dexamethasone on human podocytes. Kidney Int 2006, 70:1038-1045.
48. Mathieson P.W. Proteinuria and autoimmunity-an overstated relationship?. N Engl J Med 2008, 359:2492-2494.
49. Faul C., Donnelly M., Merscher-Gomez S., Chang Y.H., Franz S., Delfgaauw J., et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporin A. Nat Med 2008, 14:931-938.
50. Wilmer W.A., Rovin B.H., Hebert C.J., Rao S.V., Hebert L.A. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003, 14:3217-3232.
51. Barton M. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol 2008, 4:490-501.
52. Golgert W.A., Appel G.B., Hariharan S. Recurrent glomerulonephritis after renal transplantation: an unsolved problem. Pediatr Nephrol 2008, 3:800-807.
53. Fine R. Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following transplantation in children. Pediatr Nephrol 2007, 22:496-502.
54. Ijpelaar D.H., Farris A.B., Goemaer N., Amann K., Goldschmeding R., Nguyen T.Q. Fidelity and evolution of recurrent FSGS in renal allografts. J Am Soc Nephrol 2008, 19:2219-2224.
55. Fervenza F.C., Fitzpatrick P.M., Mertz J., Erickson S.B., Liggett S., Letavernier E. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007, 2:326-333.
56. Gohh R.Y., Yango A.F., Morrissey P.E., Monaco A.P., Gautam A., Sharma M., et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplantation recipients. Am J Transpl 2005, 5:2907-2912.
57. Fornoni A., Sageshima J., Wei C., Merscher-Gomez S., Aguillon-Prada R., Jauregui A.N., et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011, 3. 85ra46.